Zeiss Vision has partnered with Voxelight, LLC, maker of the popular Sunscreenr UV Camera, to develop a new handheld tablet that shows consumers how much protection their eyes have from damaging ultraviolet (UV) rays and how susceptible they are to harmful exposure. Zeiss C-UV400 is designed to illustrate the amount of UV protection present in a pair of eyeglasses and is the first time eyecare professionals will be able to show patients how much of this invisible light is being blocked.
Features: Displayed on an 8-inch tablet, Zeiss C-UV400 incorporates Sunscreenr’s patent-pending UV camera technology, showing whether or not a person’s eyeglasses are protecting their skin and eyes from the sun’s harmful UV rays by using a new indoor light technology. It also showcases Zeiss UVProtect technology, which makes full UV400 protection standard in all Zeiss clear lenses.
C-UV400 technology captures images that help ECPs evaluate and improve UV protection for their patients’ eyes and eyelids. The Sunscreenr incorporates unique AI facial analysis algorithms and a new indoor light technology to recognize if a person’s eyeglasses are not adequately protecting their eyes and skin from UV.
eQlipse is an innovative new photochromic lens product.
Features:eQlipse photochromic lenses are based on a proprietary formulation that uses a combination of advanced chemistry, proprietary polymer matrix dye composite and a unique manufacturing process, according to QSpex Technologies. The polymer matrix dye composite allows for accelerated fading without compromising darkness. eQlipse reaches its darkest state faster than leading competitors, QSpex Technologies reports. With a fade rate of 0.35 (%T/sec) within the first two minutes, eQlipse is more than two times faster than the leading competitors at fading back to a clear state from its fully darkened state and is also the clearest photochromic in a non-activated state.
“The performance integrity generated by our patented photochromic solution is unmatched,” says Kai Su, PhD, the founder of QSpex Technologies. “Produced via a highly controlled and automated coating process in a clean room environment, eQlipse’s technology is a significant improvement compared to existing photochromic lenses in three critical areas: fade time, supply chain efficiency and cost.”
Availability: eQlipse photochromic finished stock lenses will initially be available in grey and brown, CR-39 1.49 and polycarbonate 1.59 indices, with 1.67 hi-index, 1.71 hi-index and additional colors coming soon
The Screw Starter is a handy tool for adjusting frames.
Features: Aligning tiny nosepad and hinge screws using your fingers, can be painful and frustrating. Then the balancing act begins as you reach for the driver to thread the screw into the hole. Too often the screw dislodges and drops into the great void of lost screws. The Screw Starter is tall and slender, making it easy for you to insert the screw and start threading it into position.
The Screw Starter is 4.25 inches long and sells for $11.95.
Alcon unveiled the iLux MGD Treatment System at the SECO International 2019 annual meeting held recently in New Orleans. The device, which received approval from the Food and Drug Administration in December 2017, helps eyecare professionals provide comprehensive in-office treatment for their patients with dry eye disease.
Features: The innovative and personalized iLux MGD Treatment System addresses Meibomian Gland Dysfunction (MGD), a leading cause of dry eye. Handheld and portable, the iLux Device with Smart Tip Patient Interface enables ECPs to directly target a patient’s blocked Meibomian glands through the application of light-based heat and compression under direct visualization. The device expands the company’s current dry eye treatment offerings and allows practitioners to tailor treatment to the needs of each of their patients with dry eye disease in a matter of minutes.
The iLux device is indicated for the application of localized heat and pressure therapy in adult patients with chronic disease of the eyelids, including Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye. Do not use the iLux Device in patients with the following conditions: Patients whose pupils have been pharmaceutically dilated; patients who have undergone ocular surgery within prior 12 months; patients with ocular injury or trauma, chemical burns or limbal stem cell deficiency (within prior three months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior three months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior three months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids.alcon.com
Myco Industries has released AB Max, a new doctor’s treatment for anterior blepharitis. The AB Max is an adapter that allows eyecare professionals to increase the functionality of their Algerbrush by converting it into a multipurpose device for treatment of the same conditions as a standard Algerbrush, as well as an advanced doctor treatment for anterior blepharitis.
Features: John Choate, chairman of Myco and one of the inventors of the first doctor’s treatment for blepharitis, designed the AB Max to provide medical professionals with advanced functionality utilizing two onboard computers and propriety tips specifically designed to treat anterior blepharitis. The AB Max offers the same forward and reverse functionality as competitive devices, but also has a patent pending pulse mode specifically engineered to remove even the most tenacious scurf and debris, while massaging the anterior eyelid margins for better patient outcomes.
Myco Industries, Inc., has been designing and manufacturing ophthalmic/optometric devices since 1993. Algerbrush is a trademark of The Alger Companies. Myco Industries is not
affiliated with Alger Companies.
First-of-its-kind automated test that allows optometrists to quickly and objectively identify functional vision issues that affect a host of everyday activities. Once a problem is identified, Functional Vision EyeQ automatically recommends computer-based exercises for patients to do at home, under the supervision of their optometrist.
Features: Functional vision is how well the eyes and brain work together to process what is seen and is essential to quality of life. When functional vision issues are left untreated, life’s most basic activities—such as driving, reading, having good balance and coordination, walking and playing a sport—are negatively impacted and affect how well one navigates the world. While today’s standard eye exam checks for static visual acuity as well as physical health for such diseases as glaucoma and cataracts, it has not until now been able to effectively evaluate how the two eyes function together.
Through a series of quick, gamified tests, Functional Vision EyeQ is able to identify issues with dynamic vision skills, including eye alignment, eye teaming, depth perception, object tracking, gross visual motor, and visual perception and integration. Once completed, the test generates easy-to-read and quantifiable reports that foster doctor-patient communication and understanding of identified conditions, as well as a customized home-based treatment plan.
Functional Vision EyeQ tests are conducted using the RightEye eye-tracking system, the first office-friendly all-in-one-solution for vision-derived health testing, tracking eye movements and correlating them to health issues. The device is not much bigger than a laptop, works wired or wirelessly, can be operated by any office personnel and generates reports in moments.